BenevolentAI: drug research startup goes on hiring spree as UK’s artificial intelligence sector booms
Benevolent is one of five private AI companies that has reached a valuation of more than $1bn, according to CB Insights
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Drug discovery startup BenevolentAI has begun a major hiring spree, as it seeks to take advantage of the current boom in the UK’s artificial intelligence and machine learning sector.
The London-based startup, valued at $1.7bn (£1.33m) according to data firm CB Insights, is seeking to hire 50 new staff across AI, data science and bioinformatics, software engineering and medicinal science.
“We are already bursting at the seams of our current office space so alongside this hiring spree we’ll be moving to a much larger London office later in the year,” said Ken Mulvany, founder of BenevolentAI.
Benevolent is one of five private AI companies that has reached a valuation of more than $1bn, according to CB Insights. The startup, founded in 2013, focuses on using machine learning to help parse medical data - from existing studies to new papers - to speed up drug discovery.
The company has so far raised $140m (£109.5m) from investors including Lansdowne Partners and Woodford Investment Management. In 2014 the company signed a conditional £585m ($747.8m) deal with an unnamed US pharma company for potential Alzheimer’s treatments, according to filings with Companies House.
Benevolent employs around 70 people in the UK and US. In September 2016 it hired Jerome Pesenti, a former executive at IBM’s Watson platform.
The UK’s vote to leave the European Union has created economic uncertainty and raised questions about the development of artificial intelligence and the country’s ability to attract engineering, software and security talent. Cities including Paris have been battling to attract companies away from the UK as well as entrepreneurs and funding for startups.
Despite this, the UK has recently emerged as one of the dominant hubs for AI, hosting a batch of high-profile tech startups in the sector that have gone on to be acquired by US tech firms, including Twitter’s purchase of London-based artificial intelligence startup Magic Pony Technology in June, language processing company SwiftKey’s sale to Microsoft in February 2016, and Alphabet’s £400m acquisition of London AI startup DeepMind in 2014.
Most recently, SoftBank led a $502m investment in Improbable Worlds, a London-based virtual reality startup, in one of the UK’s largest venture capital deals.
London is also only behind San Francisco and New York in terms of developers, according to a report Wednesday from Stack Overflow Internet Services, a website for coders. The number of developers in the UK capital has increased 11 per cent during the past twelve months to 418,000, compared to San Francisco Bay Area and New York, home to around 661,000 and 432,000 developers respectively.
Cloudreach, backed by investors including private equity giant Blackstone and based in London, announced plans Wednesday to hire 100 new developers.
Bloomberg
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments